PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Sanofi releases AVAXIM Junior in the UK

Therapy provides immunisation against infection caused by hepatitis A in children aged 12 months to 15 years.

Sanofi has revealed that it is launching AVAXIM Junior across the UK. The treatment is an inactive hepatitis A vaccine for use in children aged 12 months to 15 years and has been developed to prevent infection caused by the hepatitis A virus.

The schedule consists of two vaccine doses injected by the intramuscular route, administered six to 36 months apart, although seven years can elapse between doses.

The launch follows pivotal data from 20 clinical studies across 14 countries in Europe, the Middle East, Asia and the Americas. These trials also involved over 6,200 children aged 12 months to 15 years who have received at least one dose of the vaccine.

The results duly demonstrated that AVAXIM Junior is impactful in inducing a protective antibody response within two weeks in over 95% of individuals and in almost 100% before the booster dose was administered six months after the initial dose.

Rebecca Catterick, UK and Ireland Sanofi vaccines general manager explained: “Hepatitis A is one of the most prevalent travel-related vaccine-preventable diseases, so the availability of effective options like AVAXIM Junior will offer parents peace of mind knowing that they can help protect their children when travelling to high-risk areas.”

Hepatitis A remains one of the most common vaccine-preventable, viral infections across the world. The condition is largely transmitted through contaminated food and water or by direct contact with an infectious person.

Prevalence is closely related to socio-economic conditions and is, therefore, much more common in developing countries with poor sanitary conditions and hygiene practices. It is also the most common form of viral hepatitis and the third most common vaccine-preventable infection among global travellers.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026